The number of targeted therapies available for the treatment of different cancers increases annually. However, for many of these agents, we do not have effective predictive biomarkers. The result is that patients who might benefit for certain therapies are not receiving them, and patients receive therapies from which they receive no benefit. In many cases, it is likely that an individual drug might be effective in only a small subset of a particular cancer, so that without a validated predictive biomarker, introduction to that cancer is impossible. W propose a novel and generalizable functional predictive biomarker approach, based on measuring death signaling early in the response to targeted therapies. We hypothesize that if we could identify those cancer cells that induce the strongest activation ofthe mitochondrial apoptotic pathway at early time points in response to a drug, we could thus identify those tumors that are most likely to respond in vivo. We are greatly assisted in this approach by our development of a novel tool, BH3 profiling, which can measure a cell's proximity to the threshold of apoptosis. Our approach is to treat cells with drugs, measure at short time points the extent to which apoptotic signaling is forcing cells toward the threshold of apoptosis, a method we call Dynamic BH3 Profiling. As we will show, we are now adept at making such measurements. Moreover, we already have exciting preliminary data that suggests that those cells that are pushed the most are also those that are destined to choose death as a cell fate. We propose to develop Dynamic BH3 profling first in AML cell lines, and then in murine AML primagrafts. Our output will be a set of drugs for which we have validated Dynamic BH3 profiling as a predicitve biomarker in vivo. These drugs might be useful as single agents, or as agents to increase priming to enhance sensitiity to conventional, curative agents. Acute myelogenous leukemia (AML) is an attractive disease in which to test our ideas because of our established expertise, established relationships, and access to clinical samples. Dynamic BH3 profling has the potential to expand the pharmacopeia and personalize therapeutic decision making for the AML patient.

Public Health Relevance

The number of Innovative targeted therapies for cancer is increasing. However, oncologists still do not have the information they need to make sure that individual cancer patients are being matched with the targeted therapies that best meet their needs. In this application we propose a novel approach, dynamic BH3 profling, to personalizing cancer therapy by measuring changes in cancer cells induced by targeted therapies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Hemming, Matthew L; Lawlor, Matthew A; Zeid, Rhamy et al. (2018) Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A 115:E5746-E5755
Kardosova, Miroslava; Zjablovskaja, Polina; Danek, Petr et al. (2018) C/EBP? is dispensable for steady-state and emergency granulopoiesis. Haematologica 103:e331-e335
Numata, Akihiko; Kwok, Hui Si; Kawasaki, Akira et al. (2018) The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia. Nat Commun 9:1622
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
Manley, Paul W; Weisberg, Ellen; Sattler, Martin et al. (2018) Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series ""Biochemistry to Bedside"". Biochemistry 57:477-478
Ebert, Benjamin L; Libby, Peter (2018) Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers. Ann Intern Med 169:116-117
DiNardo, Courtney D; Pratz, Keith W; Letai, Anthony et al. (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19:216-228
Brien, Gerard L; Remillard, David; Shi, Junwei et al. (2018) Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife 7:
Weinberg, Olga K; Gibson, Christopher J; Blonquist, Traci M et al. (2018) Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica 103:626-633
Hoshii, Takayuki; Cifani, Paolo; Feng, Zhaohui et al. (2018) A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell 172:1007-1021.e17

Showing the most recent 10 out of 376 publications